RIGL Rigel Pharmaceuticals
Rigel Pharmaceuticals earnings company data as of 4:45 AM ET 11/1
Scheduled
1 period, newest first, nothing reported yet. Each row shows EPS above revenue.
| Period | Date | Metric | Estimate | Actual | Result |
|---|---|---|---|---|---|
| FY2026 Q3 | 5 Nov | EPS | 0.87 | — | — |
| Rev | $80.1M | — | — |
Insider trades
Open-market buys and sales by RIGL's executives, directors and 10% owners in the last 12 months, from their Form 4s
- None no insider bought on the open market
- $145K sold by 1 insider outside a trading plan
- $73K sold by 1 insider under 10b5-1 plans
-
Kamil Ali-Jackson DirectorPlanned sale$73K 2,500 shares at $29.17 17% of stakeTraded May 26 Filed May 28
-
Walter H Moos DirectorSale$145K 4,000 shares at $36.36 24% of stakeTraded Feb 20 Filed Feb 24
Also filed in the last 12 months, not counted as buying or selling: 20 share withholdings for taxes, 13 stock grants, 12 option exercises, and 1 sale to cover taxes.
SEC filings
Recent issuer filings from EDGAR, 16 shown.
| Filed | Form | Detail | Links |
|---|---|---|---|
| SCHEDULE 13G/A | — | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| 10-Q | Filing Doc | ||
| 8-K | 2.02,9.01 | Filing Doc | |
| 8-K | 5.02 | Filing Doc | |
| 8-K | 2.01 | Filing Doc | |
| 8-K | 5.02,5.07 | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| 8-K | 1.01 | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| 10-Q | Filing Doc | ||
| 8-K | 2.02,9.01 | Filing Doc | |
| 8-K | 1.02 | Filing Doc | |
| DEF 14A | Filing Doc | ||
| DEFA14A | Filing Doc | ||
| SCHEDULE 13G/A | — | Filing Doc |
No filings match this filter.
Estimates are consensus figures; SEC filings remain the official record. Not investment advice.